<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02089061</url>
  </required_header>
  <id_info>
    <org_study_id>CV205-029</org_study_id>
    <nct_id>NCT02089061</nct_id>
  </id_info>
  <brief_title>Drug Interaction Statin</brief_title>
  <official_title>A Phase 1 Open-label, Single-sequence Study to Evaluate the Effect of Coadministration of BMS-919373 on the Single-dose Pharmacokinetics of Rosuvastatin and Atorvastatin in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This purpose of this study is to assess the effects of BMS-919373 on the single dose
      Pharmacokinetics (PK) of Rosuvastatin and Atorvastatin in healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Purpose: Other - To assess the effects of BMS-919373 on the single dose PK of
      Rosuvastatin and Atorvastatin in healthy subjects
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of Rosuvastatin and Atorvastatin</measure>
    <time_frame>28 timepoints up to day 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to 72 hours (AUC(0-72)) of Rosuvastatin and Atorvastatin</measure>
    <time_frame>26 timepoints up to day 8</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T)) of Rosuvastatin and Atorvastatin</measure>
    <time_frame>28 timepoints up to day 10</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) of Rosuvastatin and Atorvastatin</measure>
    <time_frame>28 timepoints up to day 10</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax) of Rosuvastatin and Atorvastatin</measure>
    <time_frame>28 timepoints up to day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal plasma half life (T-HALF) of Rosuvastatin and Atorvastatin</measure>
    <time_frame>28 timepoints up to day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total body clearance (CLT/F) of Rosuvastatin and Atorvastatin</measure>
    <time_frame>28 timepoints up to day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety based on results of physical examinations, vital sign measurements, ECGs, 24-hour telemetry, clinical laboratory tests, and physical measurements and will also include the incidence of AEs, SAEs and AEs leading to discontinuation</measure>
    <time_frame>Up to day 10</time_frame>
    <description>Adverse Event (AE)
Serious Adverse Event (SAE)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Acute Coronary Syndromes</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Rosuvastatin + BMS-919373</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin 10 mg tablet orally once for Day 1 and 5
BMS-919373: 100 mg dose on Day 4 and 30 mg dose once daily on Days 5, 6 and 7 of Microcrystalline suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Atorvastatin + BMS-919373</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atorvastatin 40 mg tablet once for Days 1 and 5
BMS-919373: 100 mg dose on Day 4 and 30 mg dose once daily on Days 5, 6 and 7 of Microcrystalline suspension</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-919373</intervention_name>
    <arm_group_label>Cohort 1: Rosuvastatin + BMS-919373</arm_group_label>
    <arm_group_label>Cohort 2: Atorvastatin + BMS-919373</arm_group_label>
    <other_name>IKur Inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <arm_group_label>Cohort 1: Rosuvastatin + BMS-919373</arm_group_label>
    <other_name>Crestor®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <arm_group_label>Cohort 2: Atorvastatin + BMS-919373</arm_group_label>
    <other_name>Lipitor®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com.

        Inclusion Criteria:

          -  Signed Written Informed Consent form

          -  Healthy subjects as determined by no clinically significant deviation from normal in
             medical and surgical history, physical examination, physical measurements, vital
             signs, 12-lead ECG, 24-hour telemetry, and clinical laboratory tests

          -  Body mass index (BMI) of 18.0 to 32.0 kg/m2, inclusive

          -  Men and women, ages 18 to 55 yrs, inclusive

        Exclusion Criteria:

          -  Current or history of cardiovascular diseases, including arrhythmias, coronary heart
             disease, and congestive heart failure

          -  Current or history of symptomatic hypotension

          -  Current or history of liver diseases, including cirrhosis and liver failure

          -  Current or history of kidney diseases, including nephrotic syndrome, renal failure,
             nephrolithiasis, and urolithiasis

          -  Current or history of neurological diseases, including presyncope, syncope, convulsive
             disorders such as epilepsy, cerebral thrombosis and cerebral embolism, transient
             ischemic attack, and stroke; or mental disorders Exceptions for presyncope/syncope
             related to vasovagal responses are allowable at the discretion of the investigator

          -  History of significant head injury in the last 2 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2014</study_first_submitted>
  <study_first_submitted_qc>March 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2014</study_first_posted>
  <last_update_submitted>August 13, 2014</last_update_submitted>
  <last_update_submitted_qc>August 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

